Oxymetholone may increase the hypoglycemic activities of Metformin. Flumequine may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Ranolazine. Milnacipran may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus. The serum concentration of Metformin can be increased when it is combined with Trimethoprim. Levofloxacin may increase the hypoglycemic activities of Metformin. Nitroaspirin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate. Metformin may increase the hypoglycemic activities of Nateglinide. The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone. Trovafloxacin may increase the hypoglycemic activities of Metformin. Norfloxacin may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Glipizide. The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib. Gatifloxacin may increase the hypoglycemic activities of Metformin. Caroxazone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Repaglinide. The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone. The risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin. Selegiline may increase the hypoglycemic activities of Metformin. Desvenlafaxine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir. Zimelidine may increase the hypoglycemic activities of Metformin. Enoxacin may increase the hypoglycemic activities of Metformin. Furazolidone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone. Prulifloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone. Paroxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone. Metformin may increase the hypoglycemic activities of Insulin Glulisine. The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide. Methylene blue may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol. Pefloxacin may increase the hypoglycemic activities of Metformin. Phenoxypropazine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Methazolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus. The therapeutic efficacy of Metformin can be increased when used in combination with Ubidecarenone. Mesalazine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethanol is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine. Acetylsalicylic acid may increase the hypoglycemic activities of Metformin. Fluoxetine may increase the hypoglycemic activities of Metformin. Iproclozide may increase the hypoglycemic activities of Metformin. Escitalopram may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Glimepiride. The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine. Cinoxacin may increase the hypoglycemic activities of Metformin. Nandrolone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Lispro. Pargyline may increase the hypoglycemic activities of Metformin. Methyltestosterone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine. Metformin may increase the hypoglycemic activities of Mecasermin. The risk or severity of adverse effects can be increased when Iodipamide is combined with Metformin. Indalpine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide. The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin. Octamoxin may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin. Olsalazine may increase the hypoglycemic activities of Metformin. Methyl salicylate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone. The serum concentration of Metformin can be increased when it is combined with Bupropion. Metformin may increase the hypoglycemic activities of Insulin Detemir. The risk or severity of heart failure can be increased when Pregabalin is combined with Metformin. Sertraline may increase the hypoglycemic activities of Metformin. The serum concentration of Dofetilide can be increased when it is combined with Metformin. Nefazodone may increase the hypoglycemic activities of Metformin. Isocarboxazid may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Glyburide. Alaproclate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone. Pegvisomant may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Lamotrigine. The risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. Balsalazide may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Human. The serum concentration of Dalfampridine can be increased when it is combined with Metformin. Etoperidone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide. Procarbazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel. Metformin may increase the hypoglycemic activities of Chlorpropamide. Iproniazid may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Glycopyrronium. Duloxetine may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Disopyramide. Dihydrotestosterone may increase the hypoglycemic activities of Metformin. Mebanazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir. Moclobemide may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate. The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate. The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide. The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir. Harmaline may increase the hypoglycemic activities of Metformin. Testosterone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide. The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine. Trolamine salicylate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine. The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin. Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin. Levomilnacipran may increase the hypoglycemic activities of Metformin. Lipoic Acid may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Iopromide is combined with Metformin. Oxandrolone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide. Brofaromine may increase the hypoglycemic activities of Metformin. Pazufloxacin may increase the hypoglycemic activities of Metformin. Grepafloxacin may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Quinine. The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil. The serum concentration of Metformin can be increased when it is combined with Cephalexin. Carbaspirin calcium may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.